Trial · NCT02711553
Participant flow16
How many started, completed or left each group, period by period.
1 to 16 of 16
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 106 | |
| Overall Study | STARTED | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 52 | |
| Overall Study | STARTED | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 102 | |
| Overall Study | STARTED | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 49 | |
| Overall Study | Received at Least 1 Dose of Study Drug | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 104 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 52 | |
| Overall Study | Received at Least 1 Dose of Study Drug | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 102 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 48 | |
| Overall Study | COMPLETED | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 100 | |
| Overall Study | COMPLETED | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 47 | |
| Overall Study | COMPLETED | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 92 | |
| Overall Study | COMPLETED | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 45 | |
| Overall Study | NOT COMPLETED | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 6 | |
| Overall Study | NOT COMPLETED | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 5 | |
| Overall Study | NOT COMPLETED | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 10 | |
| Overall Study | NOT COMPLETED | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02711553/flow